Cartalax Peptide For Sale
Buy Cartalax peptide: 10mg, 20mg or 25mg listed purchase quantities. Compare live prices across 8 listed vendors with real cost per mg, recorded COA availability and discount codes.
Buy Cartalax peptide starting at $52.20/purchase from 8 listed vendors. Compare 10mg, 20mg and 25mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).
How much does Cartalax cost per month?
An illustrative Cartalax cost model works out to about $127.28 per month: Paramount Peptides's listed 25 mg purchase quantity at $52.49 with code WPA, divided into 2 mg amounts daily. This quantity provides 12.5 nominal portions — about 1.8 weeks at the selected cadence, before preparation losses or stability limits — for roughly $29.39 per week or $127.28 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 155 calculator runs; overall cadence comes from 45 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.
Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.
About Cartalax
Pre-clinical / research-onlyAlso known as: Ala-Glu-Asp-Pro · AEDPCartalax is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) from the Khavinson short-peptide bioregulator program, sourced for cartilage and joint-aging research. It ships as a lyophilized powder you reconstitute with bacteriostatic water, and its sequence differs from Cardiogen by a single residue.[1][4]
What to check before you buy Cartalax:
- A third-party COA with mass-spec sequence confirmation — critical for Khavinson tetrapeptides, since Cartalax (Ala-Glu-Asp-Pro) differs from Cardiogen (Lys-Glu-Asp-Pro) by only one residue and HPLC purity alone cannot distinguish them.
- A COA showing ≥98% purity by HPLC, dated within the last 6–12 months and matching the exact vial size and batch.
- Accurate vial fill matching the label; under-filled vials are a common failure mode that skews reconstitution math.
Russian single-site studies have reported Cartalax as an adjunct in age-related osteoarthritis and intervertebral-disc degeneration, with reported improvements in pain scores and joint mobility versus standard care.[3] These studies are not blinded or placebo-controlled, and no Western Phase 2 or 3 trial has been registered.
Regulatory: Not FDA-approved for any indication. Sold in Russia as a non-prescription dietary peptide; research-grade injectable material elsewhere.
Cartalax: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how Cartalax works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
Cartalax is a synthetic tetrapeptide — Alanine-Glutamate-Aspartate-Proline (Ala-Glu-Asp-Pro, AEDP) — developed by Vladimir Khavinson's laboratory as the proposed active fragment of a bovine cartilage-tissue extract.[1][4] The sequence differs from Cardiogen (Lys-Glu-Asp-Pro) by a single N-terminal residue (lysine → alanine), illustrating the Khavinson group's pattern of producing closely-related organ-specific tetrapeptides by varying one or two residues of a shared scaffold. The proposed mechanism is direct binding to gene-promoter DNA in chondrocytes, selectively modulating transcription of genes involved in collagen synthesis, extracellular-matrix turnover, and chondroprotection — rather than binding to a conventional cell-surface receptor.[2] **This mechanism is unconventional and remains poorly characterised outside the originating laboratory.** Direct sequence-specific binding of a four-amino-acid peptide to a gene-promoter region is not a recognised mode of action in mainstream molecular biology, and no laboratory outside the Khavinson group has published independent replication or biochemical characterisation of the proposed promoter-binding activity for Cartalax specifically. Meaningful English-language community discussion is effectively absent; typical research-grade protocols, drawn from the Russian literature, run 1–2 mg subcutaneous daily for 10–20-day courses, repeated once or twice per year.
Active research areas
- Adjunct in age-related osteoarthritis and disc degeneration (Russian observational)Single-site Russian studies have reported Cartalax as an adjunct in elderly patients with osteoarthritis and intervertebral-disc degeneration, with reported improvements in pain scores, joint mobility, and quality-of-life markers versus standard care.[3] The studies are non-blinded, single-site, and run by groups affiliated with the laboratory that developed the peptide.
- Short-peptide bioregulator programme (mechanism context)
- No Western Phase 2 or 3 programme
Open questions & leading hypotheses (2)
- Hypothesis: Cyclic Cartalax courses improve joint pain and function in osteoarthritis, as the Russian observational record suggests.Evidence: The Khavinson-affiliated reports describe improvements in pain and mobility versus standard care over multi-month follow-up.[3] Counter-evidence: the cohorts were non-blinded, single-site, and run by the originating laboratory; no independent group has replicated the findings; no Western Phase 2 or 3 trial has been registered or completed; and contemporary OA-trial standards require placebo-controlled, blinded designs that the published Cartalax literature does not meet.
- Hypothesis: Cartalax acts by direct binding to chondrocyte gene-promoter DNA, selectively modulating transcription of collagen and matrix genes.Evidence: The proposed mechanism is the unifying claim of the Khavinson short-peptide-bioregulator framework, supported by the group's modelling and in-vitro work on short cell-penetrating peptides.[2][4] Counter-evidence: direct sequence-specific binding of a four-amino-acid peptide to gene-promoter regions is not a recognised mainstream molecular-biology mechanism; no laboratory outside the Khavinson group has independently demonstrated promoter binding for Cartalax specifically.
Sources & references (4)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett 2002;23(suppl 3):11–144. · PMID: 12374906 link
- [2]Khavinson VKh et al. Short cell-penetrating peptides: a model of interactions with gene promoter sites. Bull Exp Biol Med 2013;154:403–410. · PMID: 23484209 link
- [3]Lin'kova NS, Khavinson VKh et al. Tissue-specific peptides in the treatment of osteoarticular pathology in elderly patients. Adv Gerontol 2014;27:104–110.
- [4]Khavinson VKh, Anisimov VN et al. Peptide bioregulation of aging: results and prospects. Biogerontology 2010;11:139–149 — programme-level review. · PMID: 19830585 link
What Cartalax Costs Right Now
WPA currently tracks Cartalax from 8 distinct vendors. In-stock Cartalax vials run from $52.20 to $67.15 — a 1.3x spread for the same compound. Ameano Peptides holds the lowest sticker price at $52.20. Normalized to milligrams, Cartalax costs $2.10/mg to $5.22/mg on this page. The best per-milligram value is the listed 25 mg purchase quantity from Paramount Peptides.
Cartalax is stocked in 3 sizes: 10 mg listed quantity; vial count not recorded; 20 mg listed quantity; vial count not recorded; 25 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.
Ranked by true cost per milligram, the Cartalax listings WPA tracks are: Paramount Peptides — 25mg at $52.49 ($2.10/mg), COA purity 99.04%; LA Peptides — 20mg at $53.99 ($2.70/mg), COA purity 99.22%; Swiss Chems — 20mg at $55.76 ($2.79/mg); Peptira — 20mg at $58.65 ($2.93/mg), COA purity 99.85%; Flawless Compounds — 20mg at $67.15 ($3.36/mg), COA purity 98.75%.
Cartalax COA Coverage Across Tracked Vendors
6 of the 8 tracked Cartalax listings (75%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 6 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 98.75% to 99.86%. 5 listings record more Cartalax in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 8/26.
To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the Cartalax offer. WPA's listing fields do not establish that a report was independently verified.
Cartalax Calculator Input Observations
In lifetime Cartalax calculator inputs, 2mg is the most frequent entered amount (61 of 155 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (22 of 45 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 2mg, Daily (7x/wk) is most frequent (15 of 28 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 25 mg of listed product divided by 2 mg gives roughly 13 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.
Cartalax Discount Codes
8 of the 8 tracked Cartalax listings carry a WPA researcher discount code. The largest live discount is 15% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.
About Cartalax
Cartalax is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) from the Khavinson short-peptide bioregulator program, sourced for cartilage and joint-aging research. It ships as a lyophilized powder you reconstitute with bacteriostatic water, and its sequence differs from Cardiogen by a single residue.
Cartalax is tracked under the Recovery Peptides category on WPA. Its reported half-life is ~few hours (bioregulator estimate). Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved for any indication.
How to Read the Cartalax Comparison
- Price per milligram — Every Cartalax listing is normalized to $2.10/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
- COA metadata and purity — 6 Cartalax listings are marked for COA availability, and 6 have a recorded purity value. These fields do not independently verify a report.
- Vials sizes — The Cartalax comparison includes 10mg, 20mg, and 25mg listed purchase quantities. Check package composition separately.
- Stock status — Live in-stock state for each Cartalax listing, refreshed on a recurring basis.
Frequently Asked Questions: Cartalax
Is it legal and safe to buy Cartalax for research?
In the US, Cartalax is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. It is a Khavinson peptide bioregulator with no approved human form, sold strictly for laboratory research. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 8 Cartalax listings from 8 vendors.
How do I verify a Cartalax COA so I'm not getting an underdosed vial?
A Certificate of Analysis (COA) may report tests for a specific Cartalax batch. Check that the report identifies the compound (actually Cartalax, not a substituted or underdosed bioregulator), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For Cartalax specifically, 6 of 8 tracked listings (75%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 6 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 8/26.
Which Cartalax vendor should I pick?
There's no single "best" Cartalax vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. 8 vendors currently carry Cartalax, and Paramount Peptides holds the best true value at $2.10/mg on the 25 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.
How much does Cartalax cost — and how do I know I'm not overpaying?
Judge Cartalax by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It most often ships in 20 mg vials, so compare $/mg across those rather than the sticker price on one vial. Tracked Cartalax listings currently run $2.10/mg to $5.22/mg across 10mg, 20mg, 25mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.
How much Cartalax do I need for one full cycle?
In lifetime Cartalax calculator inputs, 2mg is the most frequent entered amount (61 of 155 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (22 of 45 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 2mg, Daily (7x/wk) is most frequent (15 of 28 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 25 mg purchase quantity by 2 mg gives roughly 13 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.
Are discount codes available for Cartalax?
Participating Cartalax vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 8 of the 8 tracked Cartalax listings carry a code right now, the largest worth 15% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.
Where can I compare Cartalax prices and listing details?
This comparison shows 8 tracked listings for Cartalax in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.